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Abstract
BACKGROUND—Neoadjuvant aromatase inhibitor therapy has been reported to improve
surgical outcomes for postmenopausal women with clinical stage II or III hormone receptor-
positive breast cancer. A multicenter phase II clinical trial was conducted to investigate the value
of this approach for US surgical practice.
STUDY DESIGN—One hundred fifteen postmenopausal women with >2 cm, estrogen receptor
(ER) or progesterone receptor (PgR)–positive breast cancer were enrolled in a trial of 16 to 24
weeks of letrozole 2.5 mg daily before operation.
RESULTS—One hundred six patients were eligible for primary analysis, 96 underwent
operations, 7 received chemotherapy after progressive disease, and 3 did not undergo an operation.
Baseline surgical status was marginal for breast-conserving surgery (BCS) in 48 (45%), 47 were
definitely ineligible for BCS (44%), and 11 were inoperable by standard mastectomy (10%).
Overall Response Evaluation Criteria In Solid Tumors clinical response rate in the breast was
62%, with 12% experiencing progressive disease. Fifty percent underwent BCS, including 30 of
46 (65%) patients who were initially marginal for BCS and 15 of 39 (38%) patients who were
initially ineligible for BCS. All 11 inoperable patients successfully underwent operations,
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including 3 (27%) who had BCS. Nineteen percent of patients undergoing mastectomy had a
pathologic T1 tumor, suggesting that some highly responsive tumors were overtreated surgically.
CONCLUSIONS—Neoadjuvant aromatase inhibitor improves operability and facilitates BCS,
but there was considerable variability in responsiveness. Better techniques to predict response,
determine residual tumor burden before operation, and greater willingness to attempt BCS in
responsive patients could additionally improve the rate of successful BCS.
Randomized trials of neoadjuvant chemotherapy against immediate operation have been
shown to increase the rate of breast-conserving surgery (BCS) without compromising
survival.1–3 For the approximately 75% of patients with tumors that express estrogen
receptor (ER), neoadjuvant endocrine therapy is a logical alternative.4,5 This is particularly
the case for postmenopausal women with ER+ disease, where tamoxifen provides at least
twice the adjuvant treatment benefit of chemotherapy, and the response to neoadjuvant
chemotherapy, in terms of the pathologic complete response rate, is low.6,7
The practice of treating patients with inoperable breast cancer with stilbestrol was
established >50 years ago.8,9 After stilbestrol was replaced by tamoxifen in the early 1980s,
use of tamoxifen before operation continued to be explored for older patients with locally
advanced disease.10 Most recently, third-generation aromatase inhibitors have replaced
tamoxifen for this indication because there is evidence for greater efficacy as both
neoadjuvant and as adjuvant treatment.11–15 Neoadjuvant aromatase inhibitor studies have
documented objective response rates of between 37% and 60% and conversion from
mastectomy to BCS in up to 50% of patients.12–15 In these studies, progression of disease
typically occurred in ≤10% of patients. Recently, a prognostic algorithm, the Preoperative
Endocrine Prognostic Index, has been developed, which incorporates information on Ki67,
ER, and stage derived from the postneoadjuvant endocrine therapy tumor specimen to
identify groups of patients with such a low relapse rate that they can consider foregoing
adjuvant chemotherapy.16 These data establish that the benefits of neoadjuvant endocrine
therapy are very similar to neoadjuvant chemotherapy, ie, not only improving surgical
outcomes, but determining “on treatment” prognosis based on the response of the primary
tumor to neoadjuvant therapy. The formal clinical experience of neoadjuvant endocrine
therapy in the US has been largely limited to smaller single-institution series or the
contribution of a modest number of patients to international phase III trials.13,17 We
performed a multicenter, phase II trial within the US using the nonsteroidal inhibitor
letrozole in patients who were either marginal candidates or not candidates for BCS. In this
article, we discuss surgical outcomes in this study, with an emphasis on factors associated
with successful breast-conservation therapy.
METHODS
Study design
The study was an open-label, multicenter phase II trial in which eligible patients were
assigned to receive oral letrozole (Femara; Novartis Pharmaceuticals), 2.5 mg daily for 16 to
24 weeks before surgical therapy from commercial stock. Ethics committee approval was
obtained at all participating sites and the trial is registered with the National Cancer Institute
clinical trials database as NCT00084396 (http://www.cancer.gov/clinicaltrials). The clinical
objectives of the study were to document the response rate to 4 months of neoadjuvant
letrozole therapy by clinical and radiologic measurements; to document rate of improvement
in surgical outcomes; to document longterm outcomes of preoperative neoadjuvant
letrozole; and to document the safety of preoperative neoadjuvant letrozole.
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Eligible patients were postmenopausal women with previously untreated clinical stage II and
III ER− or progesterone receptor (PgR)-positive breast cancer with a good performance
status (Eastern Cooperative Oncology Group performance status 0 to 2).The tumor must
have been palpable and >2 cm in size on clinical measurement. Postmenopausal status was
defined as amenorrhea for at least 1 year, bilateral surgical oophorectomy, or follicle-
stimulating hormone and estradiol in the postmenopausal range. Concurrent hormone
replacement therapy or other endocrine agents were not allowed.
Clinical assessment
Clinical response was determined monthly with bidimensional caliper measurement of the
primary tumor and clinical staging of the axilla by physical examination. Baseline surgical
status was determined by the treating surgeon before treatment and classified as inoperable,
marginal candidate for BCS, or ineligible for BCS. Classification of baseline surgical status
was based on surgeon judgment; no a priori criteria were formulated. Response Evaluation
Criteria in Solid Tumors (RECIST) criteria were used for primary reporting of data, but
WHO response data were also recorded when a second dimension was available from the
case report form.
Imaging
All consented patients were required to undergo pretreatment imaging with mammography
and ultrasonography with repeat imaging at the 16-week visit. Followup imaging was
required if clinical progression was documented on clinical examination before the
presurgical visit at week 16. Mammograms were reviewed at the local institution and, when
available, centrally. Patients were also excluded from the central radiographic analysis when
different views were provided that were not comparable. The cranial-caudal and medial-
lateral oblique mammogram films, both pretreatment and 16 weeks posttreatment, were
digitized and saved as Digital Imaging and Communications in Medicine (DICOM) files. In
a small number of patients, a medial-lateral view was used when a medial-lateral oblique
view was not available. The Digital Imaging and Communications in Medicine files were
uploaded into the Analyze software system (Mayo Clinic, Biomedical Imaging Resource)
for performing RECIST measurements.18 An experienced radiologist (KB) measured the
longest dimension of the lesion in the cranial-caudal and medial-lateral oblique views for
pre- and posttreatment by using Image Edit (Analyze software tool) to define the perimeter
of the lesion semiautomatically. In some patients, the program delineated the boundary well,
but in other patients manual editing of the region was required to remove areas not identified
as lesion or to add areas of lesion.
Biomarker assessment
Diagnosis of invasive breast cancer was made by core needle biopsy. Tumor ER status was
determined at accruing sites according to local assays. Assignment of ER-positive or
progesterone receptor positive was defined as ≥10%nuclear staining of the invasive
component of the tumor. Similarly, HER2 data were collected from local testing results.
Operation
Operations were performed after 16 to 18 weeks of letrozole therapy, except for 14 patients
with partial response (PR) at 16 weeks, for whom an extension of up to 24 weeks was
permitted. Letrozole was continued until the day before operation. Choice and conduct of
operation to the breast and axilla was not prescribed by the protocol and was left to the
judgment of the operating surgeon and preference of the patient. Final surgical outcomes
were reported for BCS versus mastectomy.
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Analysis of categorical factors associated with surgical out-comes was performed using chi-
square tests or Fisher’s exact test with fewer than five cell counts (for marginally BCS
eligible, not BCS eligible, and not operable by standard mastecttomy). For 2 × 2
contingency tables, relative risks and 95% confidence intervals were given for mastectomy
outcomes. Wilcoxon signed rank test was used to compare repeated measurements (pre- and
postmeasurements) and also two related measurements. Waterfall plots were generated for
visualization of the relationship between a sorted continuous feature of mammographic and
clinical response and surgical outcomes. All statistical tests were two-sided and a p value
≤0.05 was considered significant. Factors with a significant p value≤0.2 from contingency
table analysis with mastectomy outcomes were selected for multivariate logistic regression.
Chi-square p values on regression coefficients and odds ratios accompanied with 95% Wald
confidence intervals were reported.
RESULTS
Study population
Information on the patient population and progress of patients through the protocol is
provided in Table 1 and Figure 1. Median patient age was 67 years (range 48 to 89 years)
and the majority (94%) had good performance status (Eastern Cooperative Oncology Group
performance status 0 or 1), indicating that most patients were not burdened by a high degree
of comorbidity. Initial tumor size was large (median 4.9 cm, range 2.3 to 12 cm) by caliper
measurement and was most often of ductal histology (56%), with the remainder recorded as
lobular (24%) or mixed (17%). One hundred fifteen patients were enrolled and 106
constituted the per-protocol population. Ninety-two underwent operations around the 16th
week, and 14 were treated on a protocol-defined optional treatment extension to the 24th
week for those who were partial responders at 16 weeks. Ten patients did not have
immediate operation after letrozole treatment; seven received neoadjuvant chemotherapy,
two had comorbidities that precluded operation, and one refused operation.
Toxicity and adverse events
Toxicities and intolerances were typical for aromatase inhibitor therapy and there were no
serious unexpected adverse events that were considered likely to be study-drug–related
(Table 2). No patient withdrew from the study because of toxicity. There were no study-
related deaths.
Clinical response
Clinical response of the primary tumor to letrozole was assessed by caliper examination and
classified by RECIST criteria in 100 patients (6 patients had inadequate data) (Table 3).
Thirteen (13%) of the patients experienced a complete response (CR), 49 (49%) had PR, and
26 (26%) had stable disease. Twelve (12%) patients experienced clinical progressive
disease. Patients with progressive disease received either neoadjuvant chemotherapy (n = 7)
or had immediate operation (n = 5). Adequate bidimensional measurements for calculation
of response by WHO criteria were obtained in 83 patients and produced very similar results
(Table 2). Median clinical tumor size after letrozole treatment was significantly smaller than
pretreatment tumor size (4.9 versus 3.0 cm; p=0.0001), as expected.
Radiologic response
Radiologic response determined by ultrasonography and mammography was examined in
subsets of patients according to data availability (Table 4). Response to letrozole recorded
by local mammography assessment was available in 56 patients, producing an overall
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response rate (CR + PR) of 38%. Overall ultrasonography response rate in 77 patients was
similar (38%). The incomplete radiographic response documentation was investigated more
with a post hoc central analysis that was conducted on 63 pre- and posttherapy
mammograms. Films were digitized (unless already digital) and an image analyzer was used
to define the borders of the tumor and a longest dimension was determined. The central
review documented an overall RECIST response of 34%, which was similar to local
mammography response data; the correlation between the percentage decreases recorded by
local versus central mammography RECIST measurements was low (Spearman correlation
coefficient 0.34; p = 0.036). This might have been, in part, because it was not possible to
determine which views the local radiologists used for response assessment. It might be
noteworthy that local mammographic assessment of CR (9%) and progressive disease (16%)
was more closely aligned with clinical measurement data, but these assessments might be
biased if the radiologist was aware of the clinician’s assessment of response.
Surgical outcomes
Forty-eight of the 96 patients (50%) who underwent operations had successful BCS. This
group included 30 (65%) who were deemed as marginal for BCS at presentation, 15 (38%)
of 39 patients deemed ineligible for BCS, and 3 (27%) of 11 patients deemed inoperable by
their surgeon based on pretreatment assessments. Of the seven patients who had disease
progression necessitating neoadjuvant chemotherapy before operation, three ultimately had
BCS and four had mastectomy. There was marked variability in the BCS rate between the
two highest accruing centers, with a 29% BCS rate recorded in one and 65% in the other.
This difference cannot be explained by pre-treatment or posttreatment clinical size because
there were no significant differences, but in the site with the higher mastectomy rate the
pathologic T size was, on average, higher (3.7 cm, range 1 – 12.2 cm versus 2.1 cm, range
1.9, 0–5.5 cm; p = 0.003). Differences in surgical practice about selection of patients for
breast conservation was not necessarily the major factor in determining the twofold
difference in BCS rates between the two centers.
Pathologic results
Pathologic staging results (Table 5) supported the conclusion that a number of patients
experienced substantial tumor downstaging with letrozole treatment. Median pathologic
tumor size was 2.1 cm (range 0.0 to 12.2 cm), which was low considering the patients
entered the study with clinical stage II or III breast cancer. Clinical response rate (CR + PR)
was 84% (32 of 38) in the pathologic stage I or 0 group versus 55% (29 of 53) in the
pathologic stage II or III group (response rate difference = 29%; 95% CI, 11.8 to 47.2%; p =
0.003). Downstaging of the axilla could not be adequately assessed in this study because
baseline node status was not systematically evaluated. The histologic subtypes of breast
cancer (ductal versus lobular versus mixed) were largely unchanged with treatment, but
there was a significant improvement in the proportion of favorable histologic grade (post-
versus pretreatment tumor samples, respectively); grade 1 in 30 (32%) versus 21 (23%),
grade 2 in 57 (60%) versus 58 (55%), and grade 3 in 8 (8%) versus 22 (23%) pre- and
posttreatment samples (p = 0.0014).
Factors associated with breast conservation
To identify factors that might be used to guide the selection of patients for breast
conservation, pathologic T stage was examined by operation type (Fig. 2). Not surprisingly,
small pathologic size (T1/2) was strongly associated with BCS (p ≤ 0.0001). But 11 (23%)
of 46 patients who had mastectomy had pathologic T stage I tumors (Fig. 2), indicating they
might have been overtreated surgically (patient choice about operation was not recorded in
the study). In addition, a similar proportion of patients with T2 tumors had BCS (18 of 46;
38%) as had mastectomy (21 of 46; 44%), suggesting that many more women could have
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had BCS. To present the complex relationships between clinical RECIST responses,
pathologic stage, and surgical outcomes, waterfall plots were constructed (Fig. 3). These
data illustrate how patients who received BCS experienced greater decreases in tumor size
by clinical examination (Fig. 3A), but reveal individual patients with highly responsive
tumors and low pathologic stage who nonetheless had a mastectomy. An examination of
waterfall plots comparing tumor response by ultrasonography (Fig. 3B) and central
mammography (Fig. 3C) with final pathologic T stage and surgical outcomes showed less
evidence of clear relationships between imaging response and pathologic size. These data
suggest that clinical examination remains the most important modality for assessing
response to treatment. To more formally identify factors associated with the surgical
approach undertaken, univariate and multivariable analyses were performed (Table 6,7).
Univariate analysis revealed the following factors were significantly associated with
mastectomy: pre-aromatase inhibitor clinical T3/4 stage versus lower stage (relative risk,
2.4; 95% CI, 1.5 to 3.69; p < 0.0001), BCS ineligible/inoperable surgical status versus
marginal candidate for BCS (relative risk, 1.84; 95% CI, 1.18 to 2.88; p = 0.0042), post-
aromatase inhibitor clinical T2/3/4 stage versus lower clinical stage (T1/0) (relative risk, 2.3;
95% CI, 1.26 to 4.10; p=0.0013). Clinical response (relative risk, 1.49; 95% CI, 1.0 to 2.2; p
= 0.06) was not significant, suggesting it was not response per se, but final clinical stage that
was the most critical factor in the decision to attempt BCS. Pathologic T3/4 stage (relative
risk, 2.3; 95% CI, 1.73 to 3.11; p < 0.0001) and N1 to 3 stage (relative risk, 2.3014; 95% CI,
1.3467 to 3.9330; p = 0.0004) were also highly significantly associated with mastectomy,
confirming that this procedure was mostly a consequence of extensive residual disease.
Factors with p values <0.2 were entered into a multivariate logistic regression model to
identify factors that were independently associated with mastectomy. Not surprisingly,
baseline tumor size (T3/4 versus T2, p = 0.012) and surgical status at baseline (other versus
marginal candidate for BCS, p = 0.019) were the most significant factors, but week-16
clinical stage T1/0 was also a factor that remained significant in the multivariate model
(T2/3/4 vs T1/0, p = 0.029). Because there were no patients in this clinical stage category at
baseline, this observation supports the notion that tumor response promotes breast
conservation.
Information on breast cancer recurrences with a median followup of 36 months (range 5 to
84 months) is available for the 106 patients. To date, eight patients have experienced distant
recurrence either alone (n = 6) or with concurrent local recurrence in two mastectomy
patients. Six of the eight died of recurrent breast cancer. Five patients have died of other
causes. Eighty-three of 96 patients are currently alive without recurrence.
DISCUSSION
Clinical response rate in this study (62%) compares favorably with the performance of the
aromatase inhibitor arms of several international phase III trials of neoadjuvant endocrine
therapy, including the letrozole arm of the P024 trial (55%), and anastrozole arms of the
Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT)
(37%) and Preoperative Arimidex Compared with Tamoxifen (PROACT) (49.7%)
trials.12,13,15 Risk of clinical disease progression during letrozole therapy in this trial was
12%, which was slightly higher than that reported in the letrozole P024 trial (8%).13 This
finding emphasizes the need for careful patient selection and better predictive tests, but
salvage with neoadjuvant chemotherapy or immediate operation is a readily available
approach for this relatively uncommon situation.
At the other end of the clinical response spectrum are those patients whose final clinical
stage is T1/0. The data we have presented suggest that these patients should be offered
breast conservation even if the imaging results are equivocal, because many of these patients
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have a favorable pathologic stage category at time of operation. Imaging approaches with
either ultrasonography or mammography were disappointing decision-making tools in this
series, with poor relationships with final pathologic size and inconsistent adherence by
investigators with protocol requirements (Table 3, Fig. 3B, C). It is conceivable that these
tests might have even been misleading in certain patients, leading to inappropriate
mastectomies in patients with minimal residual disease (Fig. 2). Data presented in Figure 3
suggest that radiologic images can overestimate the amount of residual disease, perhaps
because there is no clear discrimination between persistently dense but tumor-free fibrotic
tissue typical of successful treatment and tissue that contains persistent cancer. In addition, it
might be noteworthy that several extreme responders by digital mammography had stage I
disease but underwent mastectomy (Fig. 3C). In individual patients, a careful review of the
mammogram, perhaps using image analysis software, might be helpful. Ultrasonography has
previously been reported to be an accurate predictor of response to neoadjuvant aromatase
inhibitor therapy, but this article reflects the experience of a single center and predominantly
that of a single surgeon.14 In multicenter studies, there is much less consistency in
ultrasonography technique and a single patient can be examined by several radiologists.
Reports on difficulties with imaging response to neoadjuvant chemotherapy are similar to
the experience we report here, suggesting that poor correlation between pathologic response
and imaging response is a generic problem.19 MRI was not formally studied in this
investigation. The increased sensitivity of MRI must be balanced against the propensity of
MRI to overestimate the size of breast cancer. MRI will not necessarily improve surgical
decision making after neoadjuvant endocrine therapy.20 In the final analysis, clinical
documentation of tumor regression and an attempt at breast conservation with intraoperative
assessment of margins when necessary is likely to remain the standard of care until imaging
approaches improve.
Clinical outcomes from this trial unequivocally demonstrate that the benefits of neoadjuvant
aromatase inhibitor therapy extend to patients receiving treatment in US surgical practice.
Multivariate analysis (Table 7) indicates that there is no reason to discriminate against
younger postmenopausal women or patients with lobular carcinoma because these factors
did not impact on the incidence of successful conversion to breast conservation. At a median
followup of 3 years, it is reassuring to note the absence of local recurrence in patients
experiencing BCS. Given the indolent biology of ER-positive disease, longer followup will
be required to be certain about the local recurrence rate in this clinical setting.
Currently, a randomized trial comparing the three FDA approved aromatase inhibitors is
being conducted by the American College of Surgeons Oncology Group (ACOSOG Z1031)
to identify the most effective aromatase inhibitor in this setting. Results we report here
support continued use of clinical response by RECIST criteria as the primary endpoint,
although the number of patients in the clinical stage I or 0 (complete response) category, the
rate of breast conservation, and the final pathologic stage are all appropriate additional
informative endpoints.
In conclusion, our phase II experience with letrozole confirms the value of neoadjuvant
endocrine therapy for postmenopausal women with ER-rich tumors that require downstaging
to improve surgical outcomes. Additional investigation of this approach is warranted and
consistent benefits in terms of an improvement in surgical outcomes across multiple studies
indicate that neoadjuvant aromatase inhibitor should be considered a standard of care in the
appropriate patient population.
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This Consolidated Standards of Reporting Trials (CONSORT)–type diagram summarizes
patient progress though the protocol. †Six patients withdrew consent, two patients were
ineligible on additional investigation and one patient died before receipt of study drug.
*Fourteen patients were treated on a protocol defined extension to 24 weeks for patients
experiencing a partial response at 16 weeks who were thought to potentially benefit from
additional tumor regression. §One patient refused operation and two patients did not have
operations because of severe intercurrent illness unrelated to study drug. AI, aromatase
inhibitor; BCS, breast-conserving surgery; CTX, chemotherapy treatment; ER, estrogen
receptor; M, mastectomy.
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Pathologic T stage for neoadjuvant aromatase inhibitor treated patients (n = 96) separated by
operative outcomes. Ninety-six patients had operations after neoadjuvant endocrine therapy
alone, of whom 48 had breast-conserving surgery (BCS) (dark bars) and 48 had mastectomy
(light bars). Pathologic stage was determined by American Joint Committee on Cancer
criteria.
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Waterfall plots for (A) clinical response (Response Evaluation Criteria in Solid Tumors
[RECIST]), (B) ultrasonography response RECIST, and (C) mammography RECIST
response from central measurements. Response data, as percentage change from baseline are
plotted as a sorted continuous feature. Solid symbols, patients who underwent mastectomy;
open symbols, patients who underwent breast conservation; circles, pathologic T1/0 disease;
diamond T2 disease; triangle T3; square T4.
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Table 1
Patient Characteristics, Tumor Stage, Tumor Grade, Tumor Type, and Biomarker Status (n = 106)
Characteristic Value
Age (y), median (range) 67 (48–89)
ECOG performance status, n (%)
  0 78 (74)
  1 22 (21)
  2 6 (6)
Ethnicity, n (%)
  Caucasian 74 (70)
  African American 24 (23)
  Hispanic 6 (5)
  Asian 1 (1)
  Unknown 1 (1)
Clinical tumor size (cm), median (range) 4.9 (2.3–12.0)
T stage, n (%)
  T2 56 (53)
  T3 39 (37)
  T4 11 (10)
N stage, n (%)
  N0 66 (62)
  N1 34 (32)
  N2 6 (6)
Tumor type, n (%)
  Ductal 59 (56)
  Lobular 25 (24)
  Mixed 18 (17)
  Other† 4 (4)
Tumor grade, n (%)
  1 21 (20)
  2 58 (55)
  3 27 (25)
Biomarker status, n (%)
  ER+PgR+ 75 (71)
  ER+PgR− 30 (28)
  ER−PgR+ 1 (1)
  HER2-negative 97 (91.5)
  HER2-positive 8 (7.6)
  HER2 unknown 1 (0.9)
Nine patients excluded from analysis because of withdrawal of consent (n = 7), ineligible (n = 1), and death unrelated to disease (n = 1).
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†
Mucinous, 2 (2%); tubular, 1 (1%); papillary, 1 (1%).
ECOG, Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; PgR, progesterone receptor.
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Table 2
Summary of Adverse Events that Occured During Preoperative Letrozole Treatment (n = 106)
Total Grade ≥3
Adverse event n % n %
Hot flashes 68 64 0 0
Arthralgia 48 45 3 3
Fatigue 45 42 0 0
Night sweats 13 12 0 0
Nausea and vomiting 13 12 0 0
Gastrointestinal (all) 53 50 0 0
Neurologic (all) 46 57 0 0
Dermatologic (all) 28 26 0 0
Infection (all) 26 25 5 5
Metabolic (all) 14 13 4 4
Cardiovascular (all) 5 5 3 3
Hematologic (all) 7 7 0 0









































































































































































































































































































































































Olson et al. Page 17
Table 4
Final Surgical Outcomes According to Baseline Surgical Category
Preoperative
assessment n* BCS Mastectomy Conversion (%)
Marginal for BCS 46 30 16 30/46 (65)
Ineligible for BCS 39 15 24 15/39 (38)
Inoperable 11 3 8 3/11 (27)
Total 96 48 48 48/96 (50)
*
One patient refused operation; two patients were not operable because of unassociated illness and comorbidities and seven patients with Response
Evaluation Criteria in Solid Tumors progressive disease received neoadjuvant chemotherapy followed by breast-conserving surgery (n = 3) or
mastectomy (n = 4).
BCS, breast-conserving surgery.
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Table 5
Pathological Stage after Completion of Neoadjuvant Letrozole Therapy
Characteristic Value
Pathologic tumor size (cm), median (range) 2.1 (0.0–12.2)
T stage, n (%)
  T0 1 (1)
  T1 39 (41)
  T2 39 (41)
  T3 13 (14)
  T4 4 (4)
N stage, n (%)
  N0 39 (41)
  N1 34 (35)
  N2 13 (14)
  N3 8 (8)
  Nx 2 (2)
Pathologic stage, n (%)
  0 1 (1)
  1 21 (22)
  2A 22 (23)
  2B 20 (21)
  3A 18 (19.0)
  3B 4 (4)
  3C 8 (8)
  Stage incomplete* 2 (2)
Tumor type, n (%)
  Ductal 51 (53)
  Lobular 30 (31)
  Mixed 11 (12)
  Other† 3 (3)
  No residual tumor 1 (1)
Tumor grade, n (%)
  1 30 (32)
  2 57 (59)
  3 8 (8)
  No residual tumor 1 (1)
*
Because of lack of node evaluation.
†
Mucinous, 2 (2%); tubular, 1 (1%).
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Table 6
Univariate Analysis of Factors that Influenced the Use of Breast Conservation Surgery vs Mastectomy
Feature BCS Mastectomy p Value Relative risk* (95% CI)
Age (y), mean (SD) 66.7 (10.05) 66.6 (10.1) 0.97
Biomarker
  ER+/PR+ 34 35 0.82
  ER+/PR− 14 13
Pre-AI cT stage
  cT2 36 16
  cT3/4 12 32 <0.0001 2.4 (1.5–3.7)
Clinical N stage
  cN0 31 29 0.67
  cN1/2 17 19
Histologic subtype
  Ductal 39 33
  Lobular† 9 15 0.16
Pre-AI surgical status
  Marginal BCS 30 16
  Ineligible BCS‡ 15 24 0.0042 1.84 (1.18–2.88)
  Inoperable 3 8
Clinical response
  PR + CR 35 26
  SD + PD 11 19 0.0632 1.49 (1.0–2.2)
Post-AI cT stage
  cT0/1 24 9
  cT2/3/4 24 39 0.0013 2.27 (1.26–4.1)
Pathologic T stage
  p < T2 47 32
  pT3,4 1 16 <0.0001 2.32 (1.73–3.11)
Pathologic N stage
  pN0 28 11
  pN1–3 20 37 0.0004 2.3 (1.35–3.9)
*
Relative risks and 95% CI of having a mastectomy were calculated with a feature’s lower level as reference.
†
Includes ductal with lobular features.
‡
cT and cN indicates clinical T and N stage.
AI, aromatase inhibitor; BCS, breast-conserving surgery; CR, complete response; ER, estrogen receptor; PD, progressive disease; PR, progesterone
receptor; SD, stable disease.
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Table 7





Pre-AI clinical T stage (3/4 versus 2) 0.012 3.67 (1.3–10.1)
Pre-AI surgical status (others versus marginal) 0.019 3.21 (1.2–8.5)
Post-AI cT stage (2/3/4 versus 1/0) 0.029 3.3 (1.1–9.4)
AI, aromatase inhibitor.
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